Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | CBLB | Q13191 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596279 | 0.94 | APLNR (0.42) | APLNRGRM5MAPK8MEN1KMT2A | |
| SCHEMBL21826883 | 0.94 | APLNR (0.42) | APLNRGRM5MAPK8MEN1KMT2A | |
| SCHEMBL21827569 | 0.91 | APLNR (0.42) | APLNRGRM5MAPK8MEN1KMT2A | |
| SCHEMBL31471124 | 0.91 | APLNR (0.42) | APLNRGRM5MAPK8MEN1KMT2A | |
| SCHEMBL21826857 | 0.88 | CCR4 (0.39) | APLNRATMGRM5FGFR4MAPK8 | |
| SCHEMBL21827065 | 0.84 | APLNR (0.43) | APLNRCTSAGRM5MAPK8MEN1 | |
| SCHEMBL31471101 | 0.84 | APLNR (0.43) | APLNRCTSAGRM5MAPK8MEN1 | |
| SCHEMBL31471113 | 0.82 | APLNR (0.40) | APLNRMEN1KMT2A | |
| SCHEMBL21827107 | 0.82 | APLNR (0.40) | APLNRMEN1KMT2A | |
| SCHEMBL31471102 | 0.81 | APLNR (0.42) | APLNRGRM5MAPK8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | APLNR 1/4885LCK 4019/4885ATM 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.